Safety and Tolerability in Healthy Volunteers Clinical Trial
Official title:
Controlled, Single Ascending Volume Clinical Trial to Evaluate the Safety and Tolerability of the Adhesion Reduction Medical Device Discrete(TM) in Healthy Volunteers
This study will assess the safety and tolerability of a new liquid anti-adhesion device, Discrete(TM), in healthy volunteers, in order to determine the best volume of Discrete(TM) to go forward into clinical efficacy research. The clinical trial will progress in accordance with first-in-human study guidance from the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA). It will be conducted as a randomized, controlled, double-blinded, single ascending volume, single-center, interventional safety trial. Participants will remain blinded to treatment until end of clinical trial. A maximum of 7 cohorts will be studied to assess maximum tolerated volume of investigational medical device compared with Control Lactated Ringer's solution (LRS) administered intraperitoneally. The trial will commence with a low volume and progress in a sequential, stepwise volume-escalating schema until defined maximum tolerated volume criteria are met. Following determination of the maximum tolerated volume, it is anticipated that up to 2 additional cohorts will be enrolled, wherein all participants will also receive a single standard dose of a commonly used anticoagulant as used in surgeries. A maximum of 81 participants will be enrolled. Eligible and consented adult men and women will be sequentially enrolled within each cohort at a ratio of 6 participants on Discrete(TM) to 3 participants on Control LRS. Participants will be followed for up to 10 days after intraperitoneal application. An independent Data and Safety Monitoring Committee will closely review safety in the clinical trial.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03672604 -
A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04535752 -
A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)
|
Phase 1 | |
| Completed |
NCT04783545 -
Phase I Study of VLX-1005 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01955564 -
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
|
Phase 1 | |
| Terminated |
NCT03010046 -
Single Dose Study of ANX005 in Healthy Volunteers
|
Phase 1 |